NKF Innovation Fund Invests in Nephrogen to Advance One-Time Gene Editing Therapies for Kidney Disease

Summary

The National Kidney Foundation announced an investment in Nephrogen to advance gene editing therapies for kidney disease, including a lead program targeting polycystic kidney disease. The investment supports development of a delivery platform designed to overcome barriers in delivering genetic medicines to the kidney.